Limitation

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Fast Track, Therapy, HCP, Chronic liver disease, David Berry (inventor), Recurrence, Clostridioides difficile infection, Infection, Research, Fast track (FDA), Education, FDA, Term loan, Variometer, Growth, Use, Retirement, ID, Sale, CDI, Immunodeficiency, Oaktree Capital Management, Risk, Commercial, Graft-versus-host disease, Intensive care medicine, Medicare, Spore, Patient, Medicare Part D, Acceleration, Gastroenterology, Clostridioides, Limitation, AMR, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
  • From launch through year-end 2023, there were 2,833 completed prescription enrollment forms received for VOWST, of those 2,015 resulted in new patient starts by year-end 2023.
  • Strong adoption of VOWST since commercial launch in June 2023 with broad utilization, continued quarter over quarter growth, and significant progress achieving patient access.
  • General and administrative expenses for the fourth quarter of 2023 were $17.2 million, compared with $22.4 million for the same period in 2022.

Frigorífico Concepción S.A. Announces Consent Solicitation

Retrieved on: 
Friday, February 2, 2024
DTC, Expiration, Date, Effective date, Limitation, BofA Securities, Condition, Solicitation, Amendment, Okapi BM25, Finance Secretary (India), Issuer, Originality, Collateral, Debt, Consent, Landing slot, J.P. Morgan & Co., Sale, Information, Security (finance)

ASUNCIÓN, Paraguay, Feb. 2, 2024 /PRNewswire/ -- Frigorífico Concepción S.A. (the "Company") hereby announces the commencement of its solicitation of consents (the "Consent Solicitation") to holders of its 7.700% Senior Secured Notes due 2028 for amendments to certain provisions of the Indenture governing the 2028 Notes, dated as of July 21, 2021 (the "Indenture"), among the Company, as Issuer, Frigorífico BFC S.A. (the "Bolivian Guarantor"), as Guarantor, The Bank of New York Mellon, as Trustee, Registrar and Paying Agent (the "Trustee"), and GLAS Americas LLC, as collateral agent (the "Collateral Agent").

Key Points: 
  • As of the date of the Consent Solicitation Statement, US$300,000,000 in aggregate principal amount of the 2028 Notes remains outstanding.
  • The Concurrent New Notes Offering is being conducted concurrently with the Consent Solicitation and is conditional upon the consummation of the Consent Solicitation.
  • The Expiration Time for the Consent Solicitation is 5:00 p.m., New York City time, on February 9, 2024 (as such time may be extended by Frigorífico Concepción S.A. in its sole discretion, the "Expiration Time").
  • BofA Securities, Inc. and J.P. Morgan Securities LLC are the Solicitation Agents in connection with the Consent Solicitation.

Fuwei Shareholder Receives Partial Waiver Regarding Lock-up

Retrieved on: 
Friday, October 7, 2022
Limitation, Medicine, Electronics, Schedule 13D, Nasdaq, Letter, Holding, Schedule, Cosmetics, Tobacco, Apex

By entry into of the Letter, a total number of 605,147 ordinary shares of Fuwei Films held by Apex (the "Exempted Securities") shall be exempted from the Limitations.

Key Points: 
  • By entry into of the Letter, a total number of 605,147 ordinary shares of Fuwei Films held by Apex (the "Exempted Securities") shall be exempted from the Limitations.
  • Fuwei Films conducts its business through its wholly owned subsidiary, Fuwei Films (Shandong) Co., Ltd. ("Fuwei Shandong").
  • Fuwei Shandong develops, manufactures and distributes high-quality plastic films using the biaxial oriented stretch technique, otherwise known as BOPET film (biaxially oriented polyethylene terephthalate).
  • Fuwei's BOPET film is widely used to package food, medicine, cosmetics, tobacco, and alcohol, as well as in the imaging, electronics, and magnetic products industries.

Marijuana Strategic Ventures, Inc. (OTC: MSVI) Announces Name Change to Mushrooms, Inc., New Management and Business Model

Retrieved on: 
Tuesday, July 5, 2022
Mushroom, OTC, Board of directors, Mycology, CEO, Research and development, Research, Carbon, FINRA, GLOBE, Marketing, Growth, Company, A Strange Place to Meet, Industry, Goal, Limitation, Common stock, Terminology, Development, Articles of incorporation, Retirement, Environment, Private Securities Litigation Reform Act, Loss, State, OTC Markets Group, Creativity, Forward-looking statement, Method, Security (finance), Risk management, Mycelium, Health, Innovation

I am thrilled to announce that our new CEO, Kimberly Carlson, will lead the transition to the emerging mushroom industry.

Key Points: 
  • I am thrilled to announce that our new CEO, Kimberly Carlson, will lead the transition to the emerging mushroom industry.
  • Over the years I have watched her build companies through collective collaboration with her peers and competition.
  • Her ability to bring people together from a variety of areas is welcome as we move into the Mushroom world.
  • The effectiveness of the corporate name change and change in stock trading symbol is subject to approval by FINRA.